Why Amgen’s MariTide could rival Eli Lilly, Novo Nordisk’s obesity drugs
Unlike its rivals, which require weekly injections, MariTide offers the potential for monthly or less frequent dosing ...
BioPharma Dive3h
Antag, a startup backed by Versant and Novo, joins hunt for obesity drug alternatives
The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide ...
Zacks.com on MSN6h
Amgen Stock Falls 12% in a Month: Should You Buy the Dip?
Amgen’s AMGN stock has declined 12.1% in the past month. Late last month, Amgen announced the much-awaited 52-week top-line ...
Barchart on MSN4h
Is Amgen Stock Underperforming the Dow?
Amgen Inc. (AMGN), incorporated in 1980 and headquartered in Thousand Oaks, California, is a biotech titan that crafts ...
ENDPOINTS NEWS11h
On heels of Mar­i­Tide da­ta, Dan­ish obe­si­ty biotech dis­clos­es €80M Se­ries A
Versant is out with its third obesity biotech of the year, leading an €80 million Series A for Antag Therapeutics, a Danish ...
The New York Times8h
New York Times - Top Stories
The effort to remove President Yoon Suk Yeol reflected fury over his declaration of martial law. He lifted the order within hours after it incited protests. Members of South Korea’s opposition ...
pharmaphorum19h
Novartis pays $150m upfront for Monte Rosa degrader drug
In lab studies, the orally active drug has been shown to degrade the VAV1 protein expressed in T- and B- cells. VAV1 is thought to be a signalling protein involved in the production of pro ...
pharmaphorum19h
Endo files for bankruptcy as it agrees opioid settlement
Endo International is the latest drugmaker to file for chapter 11 bankruptcy protection in connection with opioid litigation in the US, after agreeing a $6 billion deal with creditors that ...
Reuters19h
U.S. Markets
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...